Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis

Figures & data

Table 1 Case analysis of antibiotic lock therapy study subjects

Patient	Case	Age	CRBSI pathogens	Antimicrobial lock solution (concentration)	Duration (days)	Catheter sterilization	CVC retained	Concurrent systemic therapy	Indication for CVC
1	1	57 yr	CoNS	Daptomycin (1 mg/mL) + Heparin (1,000 units/mL)	15	Y	Y	Daptomycin	TPN
2	2	54 yr	MRSA	Daptomycin (1 mg/mL) + Heparin (100 units/mL)	6	Y	Y	Daptomycin	Onc
3	3	5 mo	Klebsiella oxytoca	Gentamicin (2.5 mg/mL) + Heparin (10 units/mL)	7	Y	N	Cefotaxime + vancomycin	TPN
3	4	5 mo	Citrobacter braakii α-hemolytic Streptococcus	Gentamicin (2.5 mg/mL) + Heparin (10 units/mL)	13	Y	Y	Cefotaxime + gentamicin	TPN
3	5	6 mo	Klebsiella pneumoniae Enterobacter aerogenes α-hemolytic Streptococcus	Ethanol (70%)	14	Y	N	Cefotaxime + gentamicin + vancomycin	TPN
3	6	8 mo	Acinetobacter calcoatceticusbaumannii complex	Gentamicin (5 mg/mL) + Heparin (10 units/mL)	10	Y	N	Ticarcillin/clarulanate + gentamicin	TPN
3	7	9 mo	CoNS	Vancomycin (10 mg/mL) + Gentamicin (5 mg/mL) + Heparin (10 units/mL)	12	Y	Y	Cefotaxime + gentamicin + vancomycin	TPN
3	8	9 mo	Enterobacter cloacae	Vancomycin (10 mg/mL) + Gentamicin (5 mg/mL) + Heparin (10 units/mL)	4	N	N	Cefotaxime + gentamicin + metronidazole + vancomycin	TPN
3	9	10 mo	Enterobacter cloacae	Gentamicin (5 mg/mL) Heparin (10 units/mL)	8	Y	N	Gentamicin	TPN
4	10	18 yr	CoNS	Vancomycin (10 mg/mL) + Gentamicin (5 mg/mL) + Heparin (5,000 units/mL)	9	Y	N	Vancomycin	HD
4	11	18 yr	CoNS	Vancomycin (5 mg/mL) + Heparin (5,000 units/mL)	14	N	Y	Vancomycin	HD
5	12	17 yr	CoNS MRSA	Vancomycin (5 mg/mL) + Heparin (1,000 units/mL)	5	N	Y	Cefazolin + vancomycin + rifampin	HD
6	13	5 mo	MRSA	Vancomycin (5 mg/mL) + Heparin (10 units/mL)	13	Y	Y	Clindamycin + gentamicin + vancomycin	TPN
6	14	7 mo	MRSA	Ethanol (70%) + Vancomycin (5 mg/mL) + Heparin (10 units/mL)	8	N	N	Vancomycin	TPN
6	15	7 mo	MRSA	Ethanol (70%) + Vancomycin (5 mg/mL) + Heparin (10 units/mL)	8	Y	Y	Vancomycin + gentamicin + rifampin	TPN
6	16	15 mo	Enterococcus hirae	Vancomycin (5 mg/mL) + Heparin (10 units/mL)	5	N	N	Vancomycin + gentamicin	TPN
6	17	22 mo	Acinetobacter baumannii	Gentamicin (5 mg/mL) + Heparin (10 units/mL)	15	Y	Y	Ceftazidime	TPN
7	18	1 mo	MRSA	Vancomycin (5 mg/mL)	6	Y	N	Vancomycin + gentamicin	TPN
8	19	3 mo	CoNS	Vancomycin (5 mg/mL) + Heparin (10 units/mL)	12	Y	Y	Ceftriaxone + vancomycin	TPN
9	20	79 yr	CoNS	Daptomycin (1 mg/mL) + Heparin (100 units/mL)	5	Y	Y	Daptomycin	Onc
10	21	75 yr	α-hemolytic Streptococcus	Daptomycin (1 mg/mL) + Heparin (100 units/mL)	8	Y	N	NA	Onc
11	22	55 yr	Enterococcus faecalis	Vancomycin (5 mg/mL)+ Heparin (5,000units/mL)	5	N	N	Vancomycin	Onc
12	23	82 yr	CoNS	Daptomycin (1 mg/mL) + Heparin (100 units/mL)	14	Y	Y	Daptomycin	Onc
13	24	56 yr	CoNS	Daptomycin (1 mg/mL) + Heparin (100 units/mL)	8	Y	Y	Daptomycin	Onc
14	25	20 yr	Klebsiella oxytoca	Gentamicin (5 mg/mL) + Heparin (1,000 units/mL)	4	Y	N	Piperacillin/Tazobactam + gentamicin	HD
15	26	11 yr	CoNS	Vancomycin (10 mg/mL) + Heparin (20 units/mL)	13	N	N	Vancomycin + levofloxacin	^bOther